共 27 条
[1]
Neu HC,chin NX.In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy . 1994
[2]
Matsuda S,Oh K,Hirayama H,et al.Clinical study of levofloxacin on the infections diseases in the field of obstetrics and gynecology. Journal of Chemotherapy . 1992
[3]
Appelbaum PC,Spangler SK,Jacobs MR.Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents,including RP 59500,biapenem,trospectomycin and piperacillin/tazobactam. Journal of Antimicrobial Chemotherapy . 1993
[4]
Yura J,Shinagawa N,Ishikawa S,et al.Clinical evaluation of levofloxacin,a new quinolone,in patients with surgical infections. Journal of Chemotherapy . 1992
[5]
Watanabe T,Akieda Y,Suzuki T,et al.Clinical trials of new quinolone,Sparfloxacin,in skin and skin structure infections. Drugs . 1993
[6]
Matsuda S.Clinical experience with sparfloxacin in the treatment of gynaecological infection. Drugs . 1993
[7]
Onderdonk AB.Efficacy of trovafloxacin(CP-99.219)a new fluoroquinolone in animal model of intraabdominal sepsis. Infectious Diseases in Clinical Practice . 1996
[8]
Goldstein EJ.Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. Clinical Infectious Diseases . 1993
[9]
Finegold SM,George WL.Anaerobic infections in humans. . 1989
[10]
Wexlder HM,Molitoris E,Finegold SM.In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrobial Agents and Chemotherapy . 1992